New User:

Forgot your password?

Stock Market & Financial Investment News

News For AVEO;ODP;RAD;AMAT;NAVB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 29, 2015
20:14 EDTODPRegulators preparing to block Staples-Office Depot merger, NY Post says
Subscribe for More Information
November 25, 2015
07:25 EDTRADDeutsche Bank sees no competing bid for Rite Aid
Subscribe for More Information
November 23, 2015
10:51 EDTRADOptions with increasing implied volatility: TERP BRCM CHK RAD POM
05:56 EDTRADStocks with implied volatility below IV index mean; WMT RAD
Subscribe for More Information
November 20, 2015
11:13 EDTAMATIntel, semi equipment stocks rise following chip giant's guidance
Intel (INTC) is climbing after the chip maker said at its analyst day meeting yesterday that it expects its revenue to grow by a mid-single digit percentage in fiscal 2016, up from a decline of 1% this year. On the heels of yesterday's meeting, research firm JMP Securities upgraded its rating on the stock to Outperform, saying that the company's margins and revenue are poised to climb next year. WHAT'S NEW: After conducting checks at a trade show and investor event, JMP Securities analyst Alex Gauna wrote that Intel's outlook in the cloud has improved, while its execution risk has dropped. Discussing Intel's outlook in the server chip market, Gauna wrote that the tech giant "has made significant strides" with its Xeon, Xeon Phi and Atom chips, even as rival ARM-based servers are growing more slowly than expected. Moreover, Intel is benefiting from the strong performance of its 2-in-1 notebooks, data center offerings, and enterprise PCs, Gauna reported. He believes that the chip maker's earnings are bottoming, while its revenue and margins are poised to rebound next year. Gauna raised his fiscal 2016 earnings per share estimate for the company to $2.45 from $2.10. Analysts' consensus estimate is $2.35. Gauna set a $45 price target on Intel. WHAT'S NOTABLE: Noting that Intel had predicted that its capital spending would jump 37% in 2016, KeyBanc said that this news is positive for semiconductor equipment stocks. According to the firm, Applied Materials (AMAT), Lam Research (LRCX) and Nanometrics (NANO) all have high exposure to Intel. It recommended that investors buy those stocks. PRICE ACTION: In late morning trading, Intel advanced 2% to $35, while Applied Materials rose fractionally, Lam Research gained 0.8%, Nanometrics added 1.7% and Rudolph Technologies (RTEC) jumped 4%.
08:18 EDTAMATChip equipment names have positive read through from Intel, says Pacific Crest
Subscribe for More Information
05:34 EDTRADStocks with implied volatility below IV index mean; NUAN RAD
Subscribe for More Information
November 19, 2015
06:19 EDTODPFTC looking over Staples, Office Depot transaction, NY Post reports
Subscribe for More Information
November 18, 2015
15:40 EDTRADCongressman says U.S. may need look at pharmacy competition, dealReporter says
Subscribe for More Information
05:40 EDTRADStocks with implied volatility below IV index mean; YUM RAD
Subscribe for More Information
November 17, 2015
07:56 EDTAMATUBS to hold a conference
Global Technology Conference is being held in San Francisco on November 16-18 with webcasted company presentations to begin on November 17 at 10:45 am.; not all company presentations may be webcasted. Webcast Link
November 16, 2015
16:43 EDTAMATGreenlight Capital added Apple, sold some SunEdison
Greenlight Capital gave a quarterly update on its stakes in a filing this afternoon. NEW STAKES: CNX Coal Resources (CNXC), Garmin (GRMN), Terraform Global (GLBL), and Liberty Global (LILA). INCREASED STAKES: Apple (AAPL), Michael Kors (KORS), Dillard's (DDS), UIL Holdings (UIL), and Twenty-First Century Fox (FOXA). DECREASED STAKES: SunEdison (SUNE), Micron (MU), Voya (VOYA), Applied Materials (AMAT), and SunEdison Semiconductor (SEMI). LIQUIDATED STAKES: Citizens Financial (CFG), Lam Research (LRCX), Spirit AeroSystems (SPR), Hertz (HTZ), and Macy's (M).
09:06 EDTRADDiplomat seen as compelling amid specialty pharmacy fallout
Shares of specialty pharmacy operator Diplomat Pharmacy (DPLO) and pharmacy benefit manager Express Scripts (ESRX) have each been knocked down by the negative news surrounding the sector amid the troubles faced by Valeant (VRX) and others, but an analyst at Leerink contends in a note to investors that the pullbacks in both stocks provide buying opportunities. BACKGROUND: Drugmaker Valeant and its prior specialty pharmacy partner, Philidor Rx Services, have been at the center of the firestorm engulfing the sector. Following claims that Philidor urged its employees to modify prescriptions to ensure more orders of Valeant-branded drugs rather than generics, as well as other allegations of wrongdoing, Express Scripts (ESRX) and peer CVS Health (CVS) terminated Philidor from their networks. The day after those termination announcements, Valeant said that it was severing all ties with Philidor and that the pharmacy planned to shut down operations as soon as possible, consistent with applicable laws. Valeant has subsequently said that Philidor has committed to cease operations by January 30, 2016, at the latest. More recently, Express Scripts, the nation's largest pharmacy benefit manager, announced that it stopped doing business with Linden Care, accusing it of being a "captive" pharmacy that dispenses mostly products made by Horizon Pharma (HZNP). In turn, Horizon called the idea that Linden Care is a captive pharmacy "entirely false," stating that "at best Express Scripts is being reckless in its allegations and at worse it is intentionally attempting to mislead investors." Express Scripts' move also impacted shares of Insys Therapeutics (INSY), which reportedly also used Linden Care to fulfill prescription for its drugs. DIPLOMAT LIKELY TO STAY IN-NETWORK: Leerink analyst David Larsen acknowledged that recent events indicate that Express Scripts appears to be evaluating certain retail pharmacies and their relationships with manufacturers, but he believes Diplomat's mix of drugs for diseases like multiple sclerosis, HIV, hepatitis C and cancer differentiate it as a "true" specialty pharmacy. Larsen does not think Diplomat is at risk of being excluded from the pharmacy networks of Express Scripts, CVS or UnitedHealth's (UNH) Optum, he tells investors. Larsen expects limited distribution agreements to stay an important channel strategy for drugmakers and believes these agreements are appropriate for high cost specialty drugs that require special handling and additional services to manage patient adherence. The analyst, who thinks Diplomat remains well positioned to deliver annual growth of over 30% in the next several years, keeps an Outperform rating on its shares. EXPRESS BUYING OPPORTUNITY: Larsen also thinks concerns around manufacturer and pharmacy relationships have put unwarranted pressure on shares of Express Scripts. He does not expect Express Scripts to disclose new lawsuits around rebate dollars owed over other manufacturer disputes and keeps an Outperform rating on the stock, which he views as having an "attractive" valuation. WHAT'S NOTABLE: Larsen also thinks that the specialty channel remains an opportunity for Walgreens Boots Alliance (WBA) and believes its proposed acquisition of Rite Aid (RAD) can strengthen its specialty offering. The analyst keeps an Outperform rating on Walgreens shares as well. PRICE ACTION: Over the last three months, Diplomat Pharmacy shares have declined 28%, Express Scripts has fallen 6% and Walgreens has dropped 14%.
05:30 EDTODPStocks with implied volatility above IV index mean; ODP CRM
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use